Canaccord analyst William Plovanic raised the firm’s price target on Boston Scientific to $58 from $53 and keeps a Buy rating on the shares. The analyst said we remain positive on the accelerating organic revenue growth, forthcoming product launches, and continued margin expansion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BSX: